Gerresheimer appoints Uwe Röhrhoff as interim CEO
Outgoing CEO Dietmar Siemssen has headed Gerresheimer since 2018.
Read more " 
Gerresheimer announces record sales in its core business for the financial year 2021 and raises its medium-term forecast. The two divisions „Plastics & Devices“ and „Primary Packaging Glass“ have contributed to the good start to the financial year 2022.
Gerresheimer AG, provider of Healthcare & Beauty Solutions and Drug Delivery Systems for pharma, biotech and cosmetics, is continuing to accelerate its profitable growth - according to its own statements. three years after the introduction of the strategy process formula G, which aligns business activities with megatrends such as health, sustainability and biotech and aims for sustainable and profitable growth. Adjusted Group earnings for the 2021 financial year totalled 133 million euros.
„2021 was a year of record growth for us. The results show that our strategy is paying off: We want to make Gerresheimer the leading provider of innovative solutions and systems for the health and beauty sector. We continue to invest in key growth areas and were able to increase sales in High Value Solutions by more than 30 percent in 2021. Biological Solutions grew by more than 40 per cent. We have made a good start to the 2022 financial year. For the current financial year, we expect constant profitable sales growth in the high single-digit percentage range and are raising our medium-term forecast: We will achieve an adjusted EBITDA margin of 23 to 25 percent for the Gerresheimer Group.“
Dietmar SiemssenChairman of the Management Board of Gerresheimer AG
Increased demand for plastic solutions and container glass
On the basis of strong organic sales growth of 9.3 per cent, the Gerresheimer AG reported turnover in the core business in the 4th quarter of 2021 to 438 million euros. The Plastics & Devices division achieved organic sales growth of 9.9 per cent. The division benefited in particular from strong demand for plastic solutions and medical devices.
In the 4th quarter of 2021, the „Primary Packaging Glass“ division recorded an increase in sales of strong demand for tubular and container glass an organic growth rate of 8.6 per cent. Growth was once again driven by High Value Solutions such as solutions for biologics customers, elite glass and RTF vials as well as the cosmetics business.
In addition, the Global megatrend for injection solutions unbroken. The rising demand for vaccination solutions and the increasing focus on biological medicines and self-medication are supporting the growth course of Gerresheimer. The company has optimised its Capacities in this area have been significantly increased in Europe, the USA and Asia.
Source: Gerresheimer
Gerresheimer - More news
Gerresheimer expands Wertheim site
The site, where around 160 employees currently produce ampoules and injection vials, will thus become a central competence centre for high-value packaging solutions.
Read more " 
Achim Schalk becomes new Management Board member at Gerresheimer
He succeeds Dr Lukas Burkhardt, who has decided not to extend his contract after eight years on the Executive Board and to take up a new professional challenge.
Read more " 
Packaging at the German Sustainability Award - First nominations
The 17th German Sustainability Award (DNP) honours the best products for a sustainable future. The companies nominated for the award in the packaging sector have now been announced.
Read more " 
Gerresheimer Performance Levels: Faster to the right solution
The three new performance levels for injection vials, syringes, cartridges and ampoules from Gerresheimer simplify the selection of the right product platform according to the requirements of the active pharmaceutical ingredient or the area of application.
Read more " 
Expert lectures on pharmaceutical packaging
At Pharmapack in Paris, Gerresheimer will be showcasing its portfolio of containment solutions, drug delivery systems and digital solutions.
Read more "